

DAFTAR PUSTAKA

- Abe, Masanori. 2011. *Antidiabetic Agents in Patients with Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: Metabolism and Clinical Practice*. Bentham Science Publishers Ltd. 57-69.
- Akademi Farmasi Samarinda. 2014. <http://akfarsam.ac.id/>. Diakses pada 5 November 2014 pukul 19.30 WIB.
- Almeida, S. M., C. S. Gama., N. Akamine. 2007. Prevalence & Classification of Drug-Drug Interaction in Intensive Care Patient. Hospital Israelita Albert Einstein, São Paulo (SP), Brazil. *Einstein App*. 5(4):347- 351.
- American Diabetes Association (ADA). 2004. *Standards of Medical Care for Patients with Diabetes Mellitus*. Diabetes Care: pp. 616-623.
- Aslam, M., Tan, C.K., Prayitno, A. 2007. *Farmasi Klinis: Menuju Pengobatan Rasional & Penghargaan Pilihan Pasien*. Jakarta: Penerbit PT Elex Media Kompusindo Kelompok Gramedia.
- Bateman, DN. 1981. The Pharmacokinetics of Single Doses of Metoclopramide in Renal Failure. *Eur J Clin Pharmacol*. 19(6):437-41.
- Brophy, D.F. and Gehr, W. 2002. Disorders of Potassium and Magnesium Homeostasis. In: Dipiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, 8.G., Posey, L.M. (Eds.). *Pharmacotherapy: A Pathophysiologic Approach, Fifth Edition*. New York: McGraw Hill Medical Publishing Division.
- Cardone, K.E., Bacchus, S., Assimon, M.M., Pai, A.B., Manley, H.J. 2010. Medication-related Problems in CKD. *Advances in Chronic Kidney Disease*. Vol.17:5.pg 404-412.
- Cecily, V. 2008. Nausea & Vomiting. *Pharmacotherapy A Pathophysiologic Approach 7th Edition*. New York: McGraw Hill.
- Centers for Disease Control & Prevention (CDC). 2010. USA: Clifton Rd. Atlanta.
- Chisholm-Burns, M.A., et al. 2008. *Pharmacotherapy Principles & Practices*. The McGraw-Hill Companies, Inc. United States of America.
- Cipolle, R.J., Strand, L.M., & Morley, P.C. 1998. *Pharmaceutical Care Practice*. 59, 75, 82-83, 88-90, 114-115, The McGraw-Hill Companies, New York.

- Davison SN. 2003. Pain in hemodialysis patients: prevalence, cause, severity and management. *Am J Kidney Dis* 42:1239-1247.
- DaVita. 2014. *Diabetes Is the Leading Cause of Chronic Kidney Disease*. DaVita HealthCare Partners Inc.
- Devlin, John W., Gary R. Matzke, & Paul M. Palevsky. 2008. Acid-Base Disorders. *Pharmacotherapy A Pathophysiologic Approach 7th Edition*. New York: McGraw Hill.
- Dhalmeizar , 2002. Penatalaksanaan Gagal Ginjal pra Dialisis. Kursus Nefrologi Klinik: Tata Laksana Gagal Ginjal Kronik PERNEFRI. Surabaya: *Kongres Nasional VIII Annual Meeting 2002*.
- Direktorat Bina Farmasi Komunitas & Klinik. 2005. *Pharmaceutical Care Untuk Penyakit Diabetes Mellitus*. Jakarta: Direktorat Jenderal Bina Kefarmasian & Alat Kesehatan Departemen Kesehatan.
- Djokomuljanto R. 1999. Insulin Resistance & Other Factors in the Patogenesis of Diabetic Nephropathy. *Simposium Nefropati Diabetik. Konggres Pernefri*.
- Dolores, Maria. 2014. Acute Renal Failure and Severe Thrombocytopenia Associated with Metamizole. *The National Magazine Company Ltd, London*. Volume: 25 Issue: 1 Page: 121-125.
- Edward, NC. 2012. The Safety And Tolerability Of Spironolactone In Patients With Mild To Moderate Chronic Kidney Disease. *Br J Clin Pharmacol*. 2012 Mar;73(3):447-54. doi: 10.1111/j.1365-2125.2011.04102
- Ernst, F. R. & A. J. Grizzle. 2001. Drug-Related Morbidity & Mortality: Updating the Cost-of-Illness Model. *J Am Pharm Assoc*, Vol. 41, No. 2: 192-199.
- Filho, D'Almeida EJ, da Cruz EA, Hoette M et al. 2000. Calcium Acetate Versus Calcium Carbonate in The Control of Hyperphosphatemia in Hemodialysis Patients. *Sao Paulo Med J*; 118: 179–84.
- Greene, R.J., Harris N.D. and Goodyer, L. 2000. *Pathology and Therapeutics for Pharmacist A Basic for Clinical Pharmacy Practice Second Edition*. London: Department of Pharmacy King's College University of London.
- Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan. *Endocr Pract*. 2011;17(suppl 2):1-53.

- Harrower, AD. 2011. Efficacy of Gliclazide in Comparison with Other Sulphonylureas in The Treatment of NIDDM. *PubMed*. Suppl 2:S65-7. doi: 10.3109/0886022X.2011.569107.
- Hassan, K. 2011. Acute Kidney Injury Associated with Metamizole Sodium Ingestion. *PubMed*. PMID: 21446784
- Hasslacher, C., 2001. Effect of Glicemic Control on the Development and Progression of Diabetic Nephropathy. In: Hasslacher, C. (Ed.). *Diabetic Nephropathy*, John Wiley and Son.
- Hovind, P., 2005. Inisiation, Progression and Remission of Diabetic Nephropathy. *Danish Medical Bulletin*, Vol.52, No.4. November 2005, p.119-142.
- John W. Graves, Md. 2008. Diagnosis & Management of Chronic Kidney Disease. *Mayo Foundation for Medical Education & Research*. 83(9):1064-1069.
- Joy, Melanie S. Abhijit Kshirsagar, & Nora Franceschini. 2008. Diabetes Mellitus. *Pharmacotherapy A Pathophysiologic Approach 7th Edition*. New York: McGraw Hill.
- KDIGO. 2012. Clinical Practice Guidelines for Anemia in Chronic Kidney Disease. *Kidney International Supplements*. 2, 279-335. Boston: MA, USA.
- Kovesdy, Csaba P. 2012. Metabolic Acidosis and Kidney Disease: Does Bicarbonate Therapy Slow The Progression of CKD. *Oxford Journals*. Volume 27, Issue 8, Page. 3056-3062.
- Lehmann, CR. 1985. Metoclopramide Kinetics in Patients with Impaired Renal Function and Clearance by Hemodialysis. *Clin Pharmacol Ther*. 284-9.
- Lestariningsih, 2002. Patogenesis Anemia pada Gagal Ginjal Kronik. Kursus Nefrologi Klinik: Tata Laksana Gagal Ginjal Kronik PERNEFRI. Surabaya: *Kongres Nasional VIII Anual Meeting 2002*.
- Lestariningsih. 2004. *Hipertensi pada Diabetik PIT V PERKENI 2004*. Semarang. hal 1-5.
- Levey AS, Coresh J, Balk E, et al. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, & Stratification. *Ann Intern Med*. 2003;139:137-147.
- Mahmoud, M.A. 2008. *Drug Therapy Problems & Quality of Life in Patient with Chronic Kidney Disease*. Tesis. M.Sc. Universiti Sains Malaysia.

- Mathiesen, Elisabeth. *Diagnosis of GDM*. 2014. doi.org/10.14496/dia.4104644110.9. <http://www.diapedia.org/other-types-of-diabetes-mellitus/diagnosis-of-gdm>. Diakses pada 4 November 2014 pukul 19.01 WIB.
- Medscape online. <http://reference.medscape.com/drugs>. Dikases pada 4 November 2014 pukul 20.50 WIB.
- Meyer, Daniel. 2012. *Drug Dosage Adjustments in Chronic Kidney Disease: The Pharmacist's Role*. Canada: Saskatchewan Drug Information Services College of Pharmacy and Nutrition.
- Muhlis, M. 2008. *Uji Sensitifitas Bakteri Staphylococcus Aureus yang Diperoleh dari Hapusan Faring Pasien Penderita ISPA di Poli Umum Salah Satu RSU Swasta di Yogyakarta Terhadap Antibiotika yang Biasa Digunakan*. Tugas Akhir. Yogyakarta.
- Munar, Myrna Y. 2007. Drug Dosing Adjustments in Patients with Chronic Kidney Disease. *American Family Physician*. Vol 75, No. 10: 1487-1496.
- National Institute of Diabetes & Digestive & Kidney Diseases. 2007. *National Diabetes Statistics, 2007*. Bethesda, MD: National Institutes of Health, U.S. Department of Health & Human Services, 2008.
- National Kidney Foundation. KDOQI Clinical Practice Guidelines & Clinical Practice Recommendations for Diabetes & Chronic Kidney Disease. *Am J Kidney Dis*. 2007;49:S12-154.
- Payton, CD. 1987. The Single Dose Pharmacokinetics of Bisoprolol (10 mg) in Renal Insufficiency: The Clinical Significance of Balanced Clearance. *Eur Heart J*. Dec;8 Suppl M:15-22.
- Perhimpunan Nefrologi Indonesia (PERNEFRI). 2012.
- PERKENI. 2011. *Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia*. Perkumpulan Endokrinologi Indonesia.
- Peter, W.L.S., Lewis, M.J. and Collins, A. 2002. End-stage Renal Disease. In: Dipiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., Posey, L.M. (Eds.). *Pharmacotherapy: A Pathophysiologic Approach, Fifth Edition*, New York: McGraw Hill Medical Publishing Division.
- Plantinga LC, Crews DC, Coresh J, et al. Prevalence of Chronic Kidney Disease in US Adults With Undiagnosed Diabetes or Prediabetes. *Clin J Am Soc Nephrol*. 2010;5:673-682.
- Putra, R.P, et al. 2007. *Kajian Interaksi Obat pada Pengobatan Pasien Gagal Ginjal Kronis Hipertensi di RSUP Sanglah Denpasar Tahun 2007*. Tugas Akhir.

Fakultas Matematika & Ilmu Pengetahuan Alam Universitas Udayana, Udayana.

Rahmawati, F., R. Handayani., V. Gosal, 2006. Kajian Retrospektif Interaksi Obat di Rumah Sakit Pendidikan Dr. Sardjito Yogyakarta. *Majalah Farmasi Indonesia*, 17(4), 177 – 183.

Rochman, Abdul. 2011. *Ilmu Penyakit Obstetri Dan Ginekologi*. Jakarta: e-book KlikDokter.

Rodbard HW, Jellinger PS, Davidson JA, et al. 2009. Statement By An American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel On Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control. *Endocr Pract*. 2009;15:540-59.

Saseen, Joseph J., Eric J. MacLaughlin. 2008. Hypertension. *Pharmacotherapy A Pathophysiologic Approach 7th Edition*. New York: McGraw Hill.

Soegondo S. 2004. Diagnosis & Klasifikasi Diabetes Mellitus Terkini. Dalam Soegondo S, Soewondo P & Subekti I (eds). *Penatalaksanaan Diabetes Mellitus Terpadu*. Jakarta: Pusat Diabetes & Lipid RSUP Nasional Cipto Mangunkusumo-FKUI.

Stockley, I.H. 2008. *Drug Interaction 8th Edition*. London: The Pharmaceutical Press.

Suwitra K. 2006. Penyakit Ginjal Kronik. *Buku Ajar Ilmu Penyakit Dalam Jilid I Edisi IV*. Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam FKUI, 2006. 581-584.

Talbert, Robert L. 2008. Hyperlipidemia. *Pharmacotherapy A Pathophysiologic Approach 7th Edition*. New York: McGraw Hill.

Triplitt, Curtis L., Charles A. Reasner, & William L. Isley. 2008. Chronic Kidney Disease. *Pharmacotherapy A Pathophysiologic Approach 7th Edition*. New York: McGraw Hill.

Trisna, Y. 2004. Idealisme Farmasis Klinik di Rumah Sakit. *Pengantar Farmasi Klinik*. Jakarta.

Waspadji, Sarwono. 2006. Komplikasi Kronik Diabetes: Mekanisme Terjadinya, Diagnosis dan Strategi Pengelolaan. Dalam: *Buku Ajar Ilmu Penyakit Dalam Jilid 3 Edisi IV*. Jakarta: Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia. Hal: 1908-1909.

WHO. 2003. *Drug & Therapeutics Committee a Practical Guide*. USA.